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Abstract
Introduction: Smokers receiving support in specialist centers tend to have a higher short-term quit 
rate, compared with those receiving support in other settings from professionals for whom smok-
ing cessation is only a part of their work. We investigated the difference in longer-term abstinence 
after short-term smoking cessation treatment from specialist and nonspecialist smoking cessation 
services.
Methods: We conducted a secondary analysis of data from a randomized controlled trial of self-
help booklets for the prevention of smoking relapse. The trial included 1088 short-term quitters 
from specialist stop smoking clinics and 316 from nonspecialist cessation services (such as 
general practice, pharmacies, and health trainer services). The difference in prolonged smok-
ing abstinence from months 4 to 12 between specialist and nonspecialist services was com-
pared. Multivariable logistic regression analyses were conducted to investigate the association 
between continuous smoking abstinence and the type of smoking cessation services, adjusted 
for possible confounding factors (including demographic, socioeconomic, and smoking history 
variables).
Results: The proportion of continuous abstinence from 4 to 12 months was higher in short-term 
quitters from specialist services compared with those from nonspecialist services (39% vs. 32%; 
P = .023). After adjusting for a range of participant characteristics and smoking variables, the spe-
cialist service was significantly associated with a higher rate of longer-term smoking abstinence 
(odds ratio: 1.48, 95% CI = 1.09% to 2.00%; P = .011).
Conclusions: People who receive support to stop smoking from a specialist appear to be at lower 
risk of relapse than those receiving support from a nonspecialist advisor.
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Introduction
Behavioral and pharmacological interventions are effective for smok-
ing cessation in smokers who are motivated to quit.1 Since 2001, a 
national network of NHS stop smoking services has been established 
in England to provide behavioral support and pharmacotherapy to 
smokers who would like to quit.2 In 2012/2013, the English stop 
smoking services provided support to 724 247 quit attempts, and 
generated 265 140 biochemically validated quitters (37% of quit 
attempts) at 4 weeks after the quit date.3
In the English stop smoking services, smokers motivated to quit 
may receive support in specialist clinics, primary care, pharmacy, 
or other settings.3 Previous studies reported that smokers receiving 
support in specialist centers tended to have a higher quit rate at 4 
weeks after quit dates, compared to those receiving support in other 
settings from professionals for whom smoking cessation was only a 
part of their work.4,5 However, a recent study using routine monitor-
ing data found little difference in quit rates between different types 
of smoking cessation advisors, except that smoking cessation sup-
port by nurses tended to be less effective than by specialist advisors.6 
Previous studies have only compared short-term smoking outcomes. 
For longer-term smoking outcomes, it has been assumed that the rate 
of smoking relapse would be similar among short-term quitters, irre-
spective of the type of smoking cessation support provided.4,5,7 There 
is a lack of evidence to compare the longer-term smoking outcomes 
between different types of smoking cessation advisors.
In a randomized controlled trial of self-help materials for smok-
ing relapse prevention (ISRCTN: 36980856),8 we recruited 1407 
short-term quitters and conducted follow-up interviews at 3 and 
12  months after quit dates. Participants in the treatment group 
received a set of eight self-help booklets for relapse prevention, and 
those in the control group were sent a single leaflet that is currently 
used in practice. It was found that there was no difference between 
the intervention groups in prolonged smoking abstinence from 
month 4 to 12 (37% vs. 39%, P = .51), and main findings of the trial 
will be published elsewhere.9 In the trial, we also collected data on 
the type of stop smoking services (specialist services, or from gen-
eral practice nurses, pharmacists, or community health trainers). In 
a secondary analysis, we examined whether there was a difference in 
longer-term smoking abstinence at 12 months between quitters who 
received smoking cessation treatment in different settings.
Methods
Study Participants
Study participants were those included in a randomized controlled 
trial of self-help material for smoking relapse prevention.9 The tar-
get population for this trial was people who had stopped smoking, 
as verified by carbon monoxide (CO) reading, at 4 weeks after the 
quit date, following the provision of cessation support from NHS 
stop smoking services. The biochemically verified 4-week quitter is 
defined as a treated smoker who reports abstinence from at least day 
14 after the quit date to the 4-week follow-up point and who blows 
an exhaled CO reading of less than 10 ppm.10 Quitters who were 
pregnant, unable to read booklets in English, from families at the 
same address, or younger than 18 years were excluded.
We recruited CO-validated short-term quitters from August 
2011, and initially recruited participants only from specialist 
stop smoking clinics. In May 2012, participant recruitment was 
expanded to other settings, including pharmacies, general prac-
tice, and health trainer services. Smoking cessation advisors in 
specialist stop smoking centers are more highly trained in deliver-
ing smoking cessation interventions.4 In contrast, smoking cessa-
tion counseling is only a small part of the role of practice nurses 
and pharmacists. Health Trainers also have a wider role, providing 
general support for health behavioral changes, including stopping 
smoking, dietary changes, reducing alcohol intake, and increasing 
physical activity.11
The trial achieved the recruitment target by June 2013, and 
included a total of 1407 eligible short-term quitters. Three partici-
pants died before the 12-month follow-up and were excluded from 
the analysis. Of the 1404 participants, there were 1088 participants 
from specialist stop smoking clinics, and 316 from nonspecialist ces-
sation services (including 220 from general practices, 57 from health 
trainers, and 39 from pharmacy). The follow-up rate was 86% at 
12 months, and the rate of CO verification was 85% for participants 
who reported abstinence at the 12-month follow-up.
Data Collection and Variables
Four weeks after the quit date, stop smoking advisors gathered base-
line information from participants who had consented to participate 
in the study, including participants’ demographic characteristics and 
smoking history (including previous quit attempts, number of ciga-
rettes per day, time of the first cigarette after waking up, living with 
a smoking partner or not). Study participants were then followed up 
by researchers at 3 and 12 months after quit dates. The follow-up 
interviews were conducted by telephone and involved researchers 
administering a questionnaire which asked questions about the par-
ticipant’s smoking status and process variables. In addition, at the 3 
and 12-month follow-up, we asked participants whether they used 
smoking cessation medications during 2 and 3 months after the quit 
date (For more details about questions asked and response options, 
please see the baseline and follow-up questionnaires in an online 
Supplementary Material.).
The primary outcome in the study was defined as prolonged 
abstinence from months 4 to 12, with no more than five cigarettes 
in total, and confirmed by CO < 10 ppm at the 12-month follow-
up.12 At the 12-month follow-up, participants who reported smok-
ing abstinence during the past 7 days were invited to take a CO test. 
Participants came to a clinic or a researcher visited them at home 
for this test. To optimize CO test rates, a shopping voucher (£20) 
was offered to each of the participants who attended the CO test 
at the 12-month follow-up. Participants who declined biochemical 
verification or who did not respond to follow-up were classified 
as relapsed. However, according to the trial protocol8 and Russell 
standard,12 participants who died or were known to have moved 
away from the study areas were excluded from the numerator and 
denominator, because their smoking status were not available at the 
final follow-up.
Statistical Analysis
We used t test for continuous variables and Pearson chi-square test 
for categorical variables to compare differences between stop smok-
ing services in baseline characteristics and the use of cessation medi-
cations. The statistical significance was defined when the P value was 
at most 5%. We used multivariable logistic regression analyses to 
investigate the association between continuous smoking abstinence 
from 4 to 12  months and the type of smoking cessation services 
participants had accessed, adjusted for possible confounding factors. 
The confounding factors used in the multivariable analysis were age, 
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sex, married or living with a partner, education level, unemployed 
or not, receipt of free prescription, previous quit attempts, managed 
to quit at least 4 weeks before, less than 10 cigarettes per day, first 
cigarette within 5 minutes after waking, living with a smoking part-
ner, use of nicotine replacement therapy (NRT) or varenicline during 
2 to 3 months after the quit date. The dependent variable was the 
prolonged CO-validated smoking abstinence from 4 to 12 months, 
and independent variables included type of stop smoking advisors 
(specialist vs. other), age, gender, marital status, level of education, 
in receipt of free prescription, previous quit attempts, level of nico-
tine dependence, and use of smoking cessation medications during 2 
to 3 months after the quit date. Statistical analyses were conducted 
using Stata (version 13.1).
Results
The main characteristics of participants by type of service are shown 
in Table 1. There were no statistically significant differences between 
participants from specialist services and nonspecialist services in 
demographic characteristics and smoking variables at baseline. The 
average age of participants was 48  years, and 53% were female. 
The proportion of participants who were unemployed was 10%, and 
57% were in receipt of free prescriptions. Most (89%) had previ-
ously attempted to quit smoking, and 18% were living with a smok-
ing partner (Table 1).
Table  2 shows the use of smoking cessation medications dur-
ing 2 and 3 months after the quit date. There were no statistically 
significant differences between specialist and nonspecialist services 
(as a combined category) for the use of any medications (74.2% vs. 
72.5%), NRT (36.3% vs. 36.4%), or varenicline (40.6% vs. 36.4%). 
However, there were statistically significant differences in the use of 
NRT or varenicline across individual settings (Table 2). For example, 
participants from pharmacy settings were more likely to use NRT 
compared to participants from general practice (61.5% vs. 30.9%). 
The use of varenicline was 0.0% in participants from pharmacy set-
tings, compared to 44.6% in those from general practice settings.
Figure  1 shows the rate of continuous abstinence from 4 to 
12 months by type of stop smoking service, which was relatively high 
for specialist services (39.3%, 95% confidence interval [CI] = 36.5% 
to 42.3%), low for health trainers (28.1%, 95% CI  =  17.7% to 
41.5%) or pharmacies (28.2%, 95% CI = 15.9% to 44.9%), and 
intermediate for GP practices (34.1%, 95% CI = 28.1% to 40.7%). 
When nonspecialist services were combined, the rate of continuous 
smoking abstinence was higher in participants recruited from spe-
cialist services in comparison to the rate of abstinence in participants 
from nonspecialist services (39% vs. 32%; P = .023). If the outcome 
was defined as continuous abstinence from month 2 to 12, the differ-
ence in abstinence rate between specialist and nonspecialist services 
would be similar (34% vs. 27%; P = .018).
Results of multivariable logistic regression analysis are shown in 
Table 3. After adjusting for a range of participant characteristics and 
smoking variables, the specialist service was significantly associated 
with a higher rate of longer-term smoking abstinence (odds ratio: 
1.48, 95% CI = 1.09% to 2.00%; P = .011). The longer-term smok-
ing abstinence rate was positively associated with age (P  =  .016), 
married or living with a partner (P  =  .003), fewer than 10 ciga-
rettes per day before quitting (P  =  .001), and use of NRT during 
2–3 months (P = .001). Unemployment status (P = .056), smoking 
the first cigarette within 5 minutes after waking up (P = .068), and 
use of varenicline during 2–3 months (P = .060) tended to be associ-
ated with the longer-term smoking outcome, although the associa-
tion was not statistically significant (Table 3).
Table 1. The Participant Characteristics at Baseline by Service Type
Specialist smoking cessation 
services (N = 1088)
Nonspecialist smoking  
cessation services (N = 316) P
Age: mean (SD) 48.1 (13.9) 47.0 (13.2) .182
Female: % (n) 52.4 (570) 53.8 (170) .659
Ethnicity—white: % (n) 98.6 (1070) 98.7 (312) .875
Married or living with a partner: % (n) 62.6 (680) 58.5 (185) .190
Education: % (n) (N = 1074) (N = 312)
 None 20.4 (219) 19.6 (61) .479
 GCSE 34.5 (371) 34.9 (109)
 A-level 17.8 (191) 14.7 (46)
 Degree 14.6 (157) 18.3 (57)
 Unknown 12.7 (136) 12.5 (39)
Employment status: % (n)
 Paid employment 50.9 (554) 58.9 (186) .135
 Unemployed 10.5 (114) 8.5 (27)
 Looking after home 7.8 (85) 6.0 (19)
 Retired 20.7 (225) 18.4 (58)
 Full time students 1.5 (16) 0.3 (1)
 Other 8.6 (94) 7.9 (25)
Free prescriptiona: % (n) 58.0 (625/1077) 53.5 (165/310) .132
Any previous quit attempts: % (n) 88.6 (963/1087) 91.1 (288/316) .200
Cigarettes <10 per day before quitting: % (n) 13.5 (147/1087) 15.8 (50/316) .300
First cigarette within 5 minutes after waking up: % (n) 42.9 (466/1087) 39.9 (126/316) .342
The longest time managed to stay quit before, >4 weeks: % (n) 72.6 (756/1041) 67.8 (213/314) .099
Living with a smoking partner: % (n) 18.2 (198) 19.0 (60) .750
GCSE = General Certificate of Secondary Education.
aFree prescription—The charge for a single prescription is £8.05 in the United Kingdom. Some people are entitled to free prescriptions because of their age (60 or 
over, or under 16, or aged 16 to 18 in full-education), income (on Income Support or qualified via other benefits or tax credits), or medical condition.
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Discussion
To the best of our knowledge, this is the first large scale study show-
ing that short-term quitters after receiving cessation treatment from 
specialist advisors were less likely to relapse at 12 months compared 
to those treated in nonspecialist services. The difference in the pro-
portion of smoking abstinence at 12  months was on average 7% 
between the specialist and nonspecialist services, which has impor-
tant public health implications. Assuming the same quit rate (37%) 
at 4 weeks after the quit date,3 the corresponding rate of prolonged 
abstinence from month 4 to 12 in people who set a quit date will 
be 14.4% and 11.8%, respectively. The difference in prolonged 
abstinence among people who set a quit date is likely to be larger 
than 2.6% if the support from specialist advisors is associated with 
a higher short-term quit rate than the support from nonspecialist 
advisors.4
The observed difference in longer-term smoking abstinence 
between specialist and nonspecialist services in this study is unlikely 
to be caused by confounding factors. The association between smok-
ing abstinence at 12 months and support from specialist advisors 
remained statistically significant after adjusting for participant char-
acteristics, smoking history variables, and the use of smoking cessa-
tion medications (Table 2).
Previous studies have explored possible reasons for varying 
short-term outcomes by different smoking cessation settings and 
type of advisors in the English stop smoking services. Firstly, special-
ist advisors have received more training in smoking cessation coun-
seling, compared to other health care professionals,13 and a study 
found that success rates of smoking cessation treatment were asso-
ciated with increased uptake of a national evidence-based training 
programme by advisors.14 In addition to more extensive training, 
McDermott and colleagues4 reported that specialist advisors received 
more supervision and showed greater adherence to evidence-based 
practice. Finally, it was found that group based sessions were more 
common in specialist centers than in other settings,5 and support 
provided in specialist clinics may be more intensive, compared to 
that provided in nonspecialist settings. For example, smoking cessa-
tion treatment delivered by pharmacists in Glasgow was considered 
to be of “medium-intensity”.15
The above reasons may also be pertinent in explaining the 
reduced risk of longer-term smoking relapse in short-term quitters 
who received support in specialist centers. Compared with nonspe-
cialist support, behavioral support from specialist advisors might 
have provided more effective knowledge and skills for clients to 
cope with urges to smoke. It was found that reported attempts 
by participants to do something to cope with urges were associ-
ated with a lower risk of smoking relapse.9 We further analyzed 
data and found that the proportion of participants who attempted 
to do something to cope with urges was 89.9% in participants 
from the specialist services and 84.5% in those from nonspecialist 
services.
Limitations
This was a secondary analysis of data from a trial, and it is pos-
sible that the effects observed are due to confounding factors that 
were not measured or adjusted for. The study recruited many more 
short-term quitters from specialist services (n  =  1088) than from 
nonspecialist services (n  = 316). Therefore, quitters from pharma-
cies, general practice, and health trainer services were combined in 
the main analysis and a comparison between different nonspecialist 
settings could not be conducted because of the small sample size. It 
also raises a question about the sample’s representativeness to all 
short-term quitters from nonspecialist smoking cessation services. 
Table 2. Use of Stop Smoking Medications During 2–3 Months
Any cessation  
medications % (n)
Any nicotine  
replacement therapy % (n) Varenicline % (n) Total N
Specialist services 74.6 (812) 36.3 (395) 40.6% (442) 1088
All nonspecialist services 72.5 (229) 36.4 (115) 36.4 (115) 316
 General practice 74.6 (164) 30.9 (68) 44.6 (98) 220
 Health trainer 70.2 (40) 40.4 (23) 29.8 (17) 57
 Pharmacy 64.1 (25) 61.5 (24) 0 (0) 39
Total 74.2 (1041) 36.3 (510) 39.7 (557) 1404
Pearson chi-square test:
 Specialist services vs. all 
 nonspecialist services
P = .439 P = .977 P = .176
 Across different settings  
(specialist, general practice, 
health trainer, and pharmacy)
P = .445 P = .003 P < .001
Some participants used more than one cessation medication during 2–3 months. The number of participants who did not use any cessation medications was the 
difference between the total number of participants and the number of participants who used any cessation medications. For example, 276 of the 1088 participants 
from specialist services did not use any cessation medications (ie, 1088 − 812 = 276).
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Figure 1. Continuous abstinence from 4 to 12 months in short-term quitters, 
by type of smoking cessation advisors.
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In addition, the level of training and experience amongst staff who 
provide smoking cessation support in pharmacies, general practice, 
and health trainer services may be very different.
Implications for Practice and Research
Findings from this study suggest that support from specialist smok-
ing cessation advisors is associated with not only an increased short-
term quit success, but also a reduced longer-term smoking relapse 
risk among short-term quitters. The most meaningful public health 
target of smoking cessation programmes is a lowered prevalence 
of smoking in population, rather than simply a counting of short-
term quitters most of whom will relapse in 12  months. Although 
smoking cessation support in any setting is cost-effective,16 specialist 
counseling, as an intervention that improves longer-term outcomes, 
should be emphasized.
Findings from this study have important public health and 
clinical implications, as currently there is a lack of cost-effective 
interventions for the prevention of smoking relapse in short-term 
quitters.17,18 In the English stop smoking services in 2012/2013, 
33% of smokers motivated to quit received support in specialist 
clinics, 39% in primary care, 21% in pharmacy, and 7% in other 
settings.3 The total number of people who set a quit date in nonspe-
cialist services was 485 245 in 2012/2013 in England.3 If the rate 
of prolonged abstinence was increased by 2.6%, there would be 12 
616 more people who were abstinent at 12 months. Therefore the 
use of specialist smoking cessation services should be encouraged 
to result in more quitters with longer-term abstinence. However, it 
should be stressed that smoking cessation support from nonspecial-
ist advisors is still cost-effective.16 A  large proportion of smokers 
motivated to quit have chosen to receive cessation support from 
general practice, pharmacy, and other nonspecialist advisors, based 
on individual preferences, such as perceived convenience. Health 
care professionals who provide smoking cessation counseling in 
nonspecialist settings should receive more training, or be allowed 
more time to provide smoking cessation counseling, in order to 
improve short-term and longer-term outcomes. Further research is 
needed to investigate reasons for the difference in longer term out-
comes between specialist and nonspecialist cessation support, and 
whether enhancing generalist skills in nonspecialist advisors can 
reduce longer term relapse.
In summary, longer-term smoking relapse appeared to be reduced 
in smokers who received support from specialist smoking cessation 
advisors, compared with those who received support from nonspe-
cialist advisors.
Supplementary Material
Supplementary Material can be found online at http://www.ntr.
oxfordjournals.org
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